Unsuspected DNA modification raises possibility of new carrier of heritable epigenetic information

Scientists don’t know the exact molecular nature of the epigenetic information that one generation transmits to the next. The list of candidate carriers includes proteins, noncoding RNA and the histones around which DNA winds itself. Or it could be modifications to the DNA itself that somehow get replicated when cells divide.

Now, a Harvard Medical School team has written a new chapter in the epigenetics story, with their discovery of a new position for an epigenetic modification to DNA that potentially carries heritable epigenetic information.

Over the past 20 years, a growing body of evidence has implicated chemical marks that are added to the DNA.  The best studied modifications scientists have found occur when a methyl group marks the C. More ancient organisms have other modifications, including methylation of the A.

Yang Shi, HMS professor of cell biology, overturned dogma in the field in 2004 when he showed that methylation of histones is not static. Adding a methyl group to histones—the spool around which the DNA double helix wraps to form chromosomes—can help turn a gene on or off; so does removing a methyl group. The discovery of enzymes that specifically remove methyl groups highlights the dynamic nature of histone methylation regulation, a process that is critical for stem cell biology, development and differentiation, and when it goes awry, can lead to many human diseases. Their surprising discovery was made in C. elegans, a transparent roundworm that is a widely studied model organism.

Scientists previously thought that C. elegans simply had no DNA methylation because their C letters showed no signs of the methyl modification that other animals have. It is also unknown how they can transmit epigenetic modifications across generations.

Shi’s team reports that C. elegans does in fact carry DNA methylation, but not on the C position. They found epigenetic modifications to adenine at the same location previously thought to exist only in more primitive organisms.

They also identified the enzymes that act to methylate and demethylate the A. Further bolstering their case, they showed that a transgenerational epigenetic inheritance system in C. elegans, which displays a generationally progressive reduced fertility, also progressively accumulates A methylations.

“We have identified what we think is a fundamental new layer of regulation that occurs in animals,” said Eric Greer, formerly a postdoctoral fellow in the Shi lab and now HMS assistant professor of pediatrics at Boston Children’s Hospital. “We’re excited about this because this is a modification that hasn’t previously been shown to occur in Metazoa, of which humans and worms are members.”

The more common C modification may overshadow the A modification in more recently evolved animals, said co-lead author Andres Blanco, an HMS postdoctoral fellow in pediatrics in the Shi lab.

“Maybe it’s not the dominant form of DNA methylation, but maybe it has a smaller role that is nonetheless extremely important,” he said. Harvard Medical School

Researchers use ‘knockout humans’ to connect genes to disease risk

Researchers at The University of Texas Health Science Center at Houston (UTHealth) are helping to make precision medicine a reality by sequencing entire exomes of people to assess chronic disease risk and drug efficacy.

For years, scientists have been using a method called “knockout mice,” which allows them to study gene functions by inactivating a gene in mice and then observing how it affects the mice. Now, UTHealth researchers are using new methods to study naturally occurring “knockout humans.”

Rather than genetically engineer human gene mutations in the lab, UTHealth researchers scanned 8,554 exomes, the protein-encoding portion of the genome, of African Americans and European Americans in the United States for naturally occurring mutations that inactivate a certain gene. A typical human exome has dozens of these loss-of-function gene variants.

“Years ago, we found a mutation that knocks out a gene that lowers your cholesterol. That turned into drugs that can help with cholesterol. That was with one gene. We are now sequencing lots of people and looking at where people are losing function from every gene in their body,” said Eric Boerwinkle, Ph.D., senior author, professor and chair of the Human Genetics Center and the Department of Epidemiology, Human Genetics and Environmental Sciences at UTHealth School of Public Health.

The study participants were part of Atherosclerosis Risk in Communities (ARIC), a study conducted by the National Heart, Lung and Blood Institute (NHLBI). The group was measured for 20 phenotypes related to chronic diseases, such as serum magnesium levels, triglyceride levels, blood pressure and cholesterol.

By observing how certain mutations affect health, researchers were able to identify eight new relationships between genes and diseases and confirm the already established relationship between gene variant PCSK9 and lower blood cholesterol and lower heart disease risk.

A heterozygous form of gene TXNDC5 was found to be related to Type 1 Diabetes progression and elevated fasting glucose levels. A recessive form of C1QTNF8 was related to elevated serum magnesium levels and participants who had a mutation of SEPT10 had significantly reduced lung function.

“Loss-of-function variation in certain genes, such as TXNDC5, may predispose individuals to develop disease. More research is needed to determine the exact mechanisms of these newly discovered relationships,” said Boerwinkle, who is also the Kozmetsky Family Chair in Human Genetics at UTHealth. University of Texas at Houston Health Science Center

Fracture’ prints, not fingerprints, help solve child abuse cases

Much like a finger leaves its own unique print to help identify a person, researchers are now discovering that skull fractures leave certain signatures that can help investigators better determine what caused the injury.

Implications from the Michigan State University research could help with the determination of truth in child abuse cases, potentially resulting in very different outcomes.

Until now, multiple skull fractures meant several points of impact to the head and often were thought to suggest child abuse.

Roger Haut, a University Distinguished Professor in biomechanics, and Todd Fenton, a forensic anthropologist, have now proven this theory false. They’ve found that a single blow to the head not only causes one fracture, but may also cause several, unconnected fractures in the skull. Additionally, they’ve discovered that not all fractures start at the point of impact – some actually may begin in a remote location and travel back toward the impact site.

“It’s a bit like smashing raw hamburger into a patty on the grill,” Haut said. “When you press down on the meat to flatten it, all the edges crack. That’s what can happen when a head injury occurs.”

Because piglet skulls have similar mechanical properties as infant human skulls – meaning they bend and break in similar ways – Haut and Fenton used the already deceased specimens in their research and found they were able to classify the different fracture patterns with a high degree of accuracy.

“Our impact scenarios on the piglet skulls gave us about an 82 percent accuracy rate, while on the older skulls, it improved to about 95 percent,” Fenton said.

To help them get to this level of accuracy, both researchers teamed up with Anil Jain, a University Distinguished Professor in computer science and engineering at MSU, to develop a mathematical algorithm to help classify the fractures.

“A major issue in child death cases is you never really know what happened,” Haut said. “The prosecutor may have one idea, the medical examiner another, and the defendant a completely different scenario.”

Fenton and Haut’s close relationship with medical examiners often results in them being called upon in certain, hard-to-determine cases. They’ve used this new knowledge to help solve these cases, but both are also looking to use Jain’s algorithm in an online resource that will provide even more assistance to investigators.

The team is currently developing a database, or Fracture Printing Interface, that will allow forensic anthropologists and investigators to upload human fracture patterns from different abuse cases and help them determine what most likely caused an injury.

Michigan State University

Researchers get a closer look at how the Huntington’s gene works

Huntington’s disease is caused by a mutation in the Huntington’s disease gene, but it has long been a mystery why some people with the exact same mutation get the disease more severely and earlier than others. A closer look at the DNA around the Huntington’s disease (HD) gene offers researchers a new understanding of how the gene is controlled and how this affects the disease. These findings set the stage for new treatments to delay or prevent the onset of this devastating brain disease.

Huntington’s disease is a genetic disorder that gets passed down in families, but symptoms generally don’t appear until later in life. It affects the brain and gradually worsens, causing problems with coordination and movement, mental decline and psychiatric issues. While every person has two copies of each gene – one on each chromosome – a single mutation in one copy of the HD gene means the person will suffer from the disease.

The HD gene is controlled by surrounding regions of DNA that function to turn the gene on and off. Dr. Blair Leavitt, professor in UBC’s Department of Medical Genetics, and his colleagues took a closer look at this part of the genetic code. They identified critical regions where proteins, called transcription factors, can bind to the DNA and control the function of the HD gene. Changes in these DNA regions can play both good and bad roles in the disease. In some cases, the DNA changes increase the severity of the disease and speed up the onset and in other cases it protects the person by delaying the onset of the disease.

“The gene for Huntington’s was discovered over twenty years ago but there is very little known about how the expression of this important gene is controlled,” said Leavitt, who is also a scientist with the Centre for Molecular Medicine and Therapeutics. “This study helps us understand how small genetic differences in the DNA surrounding the HD gene can both delay and accelerate the disease.”

Researchers found that when the DNA change is found on a normal chromosome with no HD mutation, it turns off the expression of the good gene and allows the mutant gene on the other chromosome to predominate, speeding up the onset of the disease. If the DNA change is found on a chromosome with the HD mutation, it turns off the bad gene and offers individuals some protection from the disease.

According to Leavitt, these findings provide critical evidence to support the development of new drugs that decrease the expression of the mutant HD gene, an approach called gene silencing. Leavitt is already involved in the testing of one gene silencing treatment that shows great promise, and will begin the first human trial of this therapy for HD later this year. University of British Columbia

New insights into how DNA differences influence gene activity, disease susceptibility

Researchers funded by the National Institutes of Health Genotype-Tissue Expression (GTEx) project have created a new and much-anticipated data resource to help establish how differences in an individual’s genomic make-up can affect gene activity and contribute to disease. The new resource will enable scientists to examine the underlying genomics of many different human tissues and cells at the same time, and promises to open new avenues to the study and understanding of human biology.

GTEx investigators reported initial findings from a two-year pilot study in several papers. These efforts provide new insights into how genomic variants – inherited spelling differences in the DNA code – control how, when and how much genes are turned on and off in different tissues, and can predispose people to diseases such as cancer, heart disease and diabetes.

‘GTEx was designed to sample as many tissues as possible from a large number of individuals in order to understand the causal effects of genes and variants, and which tissues contribute to predisposition to disease,’ said Emmanouil Dermitzakis, Ph.D., professor of genetics at the University of Geneva Faculty of Medicine, Switzerland, and a corresponding author on the main Science paper. ‘The number of tissues examined in GTEx provides an unprecedented depth of genomic variation. It gives us unique insights into how people differ in gene expression in tissues and organs.’

In the main paper, researchers analysed the gene activity readouts of more than 1,600 tissue samples collected from 175 individuals and 43 different tissues types. One way that researchers evaluate gene activity is to measure RNA, which is the readout from the genome’s DNA instructions. Investigators focused much of their analyses on samples from the nine most available tissue types: fat, heart, lung, skeletal muscle, skin, thyroid, blood, and tibial artery and nerve.

The genomic blueprint of every cell is the same, but what makes a kidney cell different from a liver cell is the set of genes that are turned on (expressed) and off over time and the level at which those genes are expressed. GTEx investigators used a methodology – expression quantitative trait locus (eQTL) analysis – to gauge how variants affect gene expression activity. An eQTL is an association between a variant at a specific genomic location and the level of activity of a gene in a particular tissue. One of the goals of GTEx is to identify eQTLs for all genes and assess whether or not their effects are shared among multiple tissues.

Investigators discovered a set of variants with common activity among the different tissue types. In fact, about half of the eQTLs for protein-coding genes were active in all nine tissues. They identified approximately 900 to 2,200 eQTL genes – genes linked to nearby genomic variants – for each of the nine tissues studied, and 6,486 eQTL genes across all the tissues. ‘We didn’t know how specific this regulation would be in different tissues,’ said co-corresponding author Kristin Ardlie, Ph.D., who directs the GTEx Laboratory Data Analysis and Coordination Center at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts. ‘The analysis showed a large number of variants whose effects are common across tissues, and at the same time, there are subsets of variants whose effects are tissue-specific.’

Comparing tissue-specific eQTLs with genetic disease associations might help provide insights into which tissues are the most relevant to a disease. The researchers also found a great deal of eQTL sharing among tissues, which can help explain how genomic variants affect the different tissues in which they are active. National Human Genome research Institute

Study finds metabolic link between bacterial ‘biofilms’ and colon cancer

A team led by scientists at The Scripps Research Institute (TSRI) and Johns Hopkins University School of Medicine has uncovered a big clue to how bacteria may promote some colon cancers.

The study used novel metabolomic technologies to reveal molecular evidence suggesting a vicious circle in which cancerous changes in colon cells promote the growth of bacterial conglomerations called biofilms, and biofilms in turn promote cancer development.

On the whole, the findings suggest that removing bacterial biofilms could be a key strategy for preventing and treating colon cancers, which currently kill about 50,000 Americans per year. The study also revealed an apparent metabolic marker of biofilm-associated colon cancers.

The research, which used sophisticated “metabolomics” techniques, was a collaboration between groups led by Gary Siuzdak, professor of chemistry, molecular and computational biology and senior director of the Scripps Center for Metabolomics at TSRI, Cynthia L. Sears, professor of medicine, oncology and molecular microbiology and immunology at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health, and David Edler, associate professor at the Karolinska Institute.

A previous study led by Sears and colleagues provided evidence that the tissue in and around cancers of the ascending colon, on the right side of the abdomen, almost always harbours bacterial conglomerations called biofilms.

“In the current study, we wanted to understand more about what was happening,” said Caroline H. Johnson, member of the Scripps Center for Metabolomics and co-first author of the new report with Christine M. Dejea of Johns Hopkins. “In particular, we wanted to determine if there was a metabolic link between the biofilm and colon cancer.”

Metabolites are small molecules in blood and tissues that are products of the myriad metabolic processes in cells. More than 10,000 distinct metabolites normally can be found in humans.

The team began the search with an “unbiased screen,” a wide-net technique—using advanced liquid chromatography and mass spectrometry and their XCMS metabolomic cloud-based platform—that registered the levels of thousands of metabolites in a set of colon tissue samples from patients at Johns Hopkins and at the Karolinska Institute in Sweden.

The data showed that polyamines were important in general and one metabolite—N1, N12-diacetylspermine—was particularly prominent, on average about nine times more abundant in cancerous tissue, compared to nearby non-cancerous tissue.

In further tests, the team found that even among cancerous samples, the same metabolite was four times more abundant in the presence of biofilms. In other words, the cancerous cells and the biofilms both seemed to be contributing to its overproduction.

With a sophisticated technique called “nanostructure imaging mass spectrometry” (NIMS), the team was able to map the precise locations of N1, N12-diacetylspermine in tissue samples, confirming its higher levels in both tumours and biofilms.

The researchers also carried out a technique called “global isotope metabolomics,” using an isotope of N1, N12-diacetylspermine to trace its metabolic fate in cells in an unbiased manner, finding that it appears to be a metabolic end-product.

That colon tumours would produce abnormally high amounts of N1, N12-diacetylspermine is not surprising. The molecule belongs to a family of metabolites called polyamines, which are known to have roles in driving cell growth and which are commonly up-regulated in cancers as well as in healthy fast-growing tissues. N1, N12-diacetylspermine itself has been observed at higher levels in colon cancer and is considered a potential biomarker for early cancer diagnosis.

But why would bacterial biofilms also be linked to higher levels of N1, N12-diacetylspermine? It turns out that bacteria, too, use polyamines to drive their own cells’ proliferation and to build biofilms. Polyamines are such ancient, ubiquitous molecules that bacteria apparently can even use those produced by their animal hosts.

Thus, biofilms may promote cancer in the colon by inducing chronic inflammation and associated cell proliferation. That increased cell proliferation would be accompanied by a rise in the production of polyamines. Resident bacteria, in turn, could use this abundance of polyamines to make more biofilms—completing the vicious circle. Along the way, levels of the by-product N1, N12-diacetylspermine would be driven higher and higher. The Scripps Research Institute

Thermometer-like device could help diagnose heart attacks

Diagnosing a heart attack can require multiple tests using expensive equipment. But not everyone has access to such techniques, especially in remote or low-income areas. Now scientists have developed a simple, thermometer-like device that could help doctors diagnose heart attacks with minimal materials and cost.

Sangmin Jeon and colleagues note that one way to tell whether someone has had a heart attack involves measuring the level of a protein called troponin in the person’s blood. The protein’s concentration rises when blood is cut off from the heart, and the muscle is damaged. Today, detecting troponin requires bulky, expensive instruments and is often not practical for point-of-care use or in low-income areas. Yet three-quarters of the deaths related to cardiovascular disease occur in low- and middle-income countries. Early diagnosis could help curb these numbers, so Jeon’s team set out to make a sensitive, more accessible test.

Inspired by the simplicity of alcohol and mercury thermometers, the researchers created a similarly straightforward way to detect troponin. It involves a few easy steps, a glass vial, specialized nanoparticles, a drop of ink and a skinny tube. When human serum with troponin — even at a minute concentration — is mixed with the nanoparticles and put in the vial, the ink climbs up a protruding tube and can be read with the naked eye, just like a thermometer. American Chemical Society

Identification of gene’s role in asthma could lead to therapy

The over-active immune cells responsible for asthma depend on the gene BCL11B to develop into mature cells, according to a study. The identification of this gene’s role could help in the search for asthma therapies.

Innate lymphoid cell 2 (ILC2), one of a recently discovered class of innate immune cells, is responsible for regenerating respiratory tissues following influenza virus infection. However, an excess of active ILC2 cells can cause lung inflammation, leading to asthma. Researchers hope that targeting BCL11B will enable them to regulate the creation of ILC2s.

‘Before now, asthma treatment has focussed on treating symptoms,’ says Professor Gordon Dougan, a senior author and group leader at the Wellcome Trust Sanger Institute. ‘Now that we have joined the dots between the development of ILC2 cells and the expression of BCL11B, we can begin looking for drug targets that will tackle asthma’s root cause.’

In previous research, it has been found that deleting both copies of the Bcl11b gene in a mouse embryo will cause the animal to die at birth. To observe the reason for this, researchers treated normal mice with Tamoxifen to disable the Bcl11b gene. Three weeks after treatment, these mice were found to have just 6 per cent of the normal number of ILC2 cells because no new ILC2 cells were developed from the progenitor cells in the blood. The treated mice became extremely vulnerable to influenza infection.

‘ These innate immune cells are essential in the fight against infection but having too many can cause serious problems ‘

Scientists also observed mice with just one copy of the Bcl11b gene, rather than the normal two copies. They were surprised to find that reducing Bcl11b expression led to significantly higher numbers of mature ILC2 cells than were found in normal, wild-type, mice. This indicates that the activity of the gene may supress the production of mature cells as well as helping early cells to develop.

‘These innate immune cells are essential in the fight against infection but having too many can cause serious problems,’ says Dr Pentao Liu, a corresponding author from the Sanger Institute. ‘BCL11B has to be there to help ILC2 progenitor cells to reach maturity but it must also be active to suppress the over-creation of mature cells. Our focus must now be on finding a way to manipulate gene expression to boost or reduce cell populations as required.’ Sanger Institute

Chameleon proteins make individual cells visible

Researchers discovered a new mechanism of how fluorescent proteins can change colour. It enables the microscopic visualization of individual cells in their three-dimensional environment in living organisms.

Researchers at ETH Zurich’s Department of Biosystems Science and Engineering in Basel have developed a new microscopy technique that enables for the first time to selectively visualize individual cells within the complex, three-dimensional tissue of a living organism. The researchers have thus succeeded in capturing spectacular microscopic images, such as in the nervous system of a zebrafish larva, a preferred model organism for research. Motor neurons in the spinal cord can be seen in the researchers’ images; at the same time, a single neuron with all its extensions is highlighted in another colour.
An observation by William Dempsey, post-doc in the group of ETH professor Periklis Pantazis, led to the new application. He worked with a special class of fluorescent proteins that change colour when irradiated with laser light of a specific wavelength. One such ‘chameleon protein’ is called Dendra 2, which normally emits green light when illuminated with blue light. The emission of Dendra 2 is however shifted into the red when it is irradiated by intensive violet or ultraviolet (UV) laser light.

Dempsey and Pantazis specifically discovered that when Dendra 2 is irradiated by both a blue and a red laser at the same time, the protein’s colour can also change to red. For this dual-colour illumination low intensity laser light is sufficient. In contrast to high intensity violet or UV irradiation it does not damage living cells.

ETH professor Pantazis and his colleagues then had an idea of how this finding could be deployed in light microscopy. Fluorescent proteins can be used to make whole cells, precise cell structures or single molecules visible. For the first time, the ETH researcher’s discovery permits a single cell or group of molecules located within a desirable part of a living organism to be highlighted with one colour, while all the other cells or molecules remain visible with another colour.

The research group showed that when used individually, two different laser beams cannot change a chameleon protein’s colour. But when the two beams are combined and directed in a way that they meet at a certain point on the object, then the proteins in focus change colour. In contrast, the proteins that are not activated at the same time by the two lasers retain their original colour.
The researchers have developed a simple and inexpensive colour filter, which can be used with the conventional confocal laser microscopes that are found in many biomedical research institutes. When mounted between the laser source and object, the filter divides the laser light into separate blue and red beams that are directed on to a small focal point on the object.

In the case of the zebrafish larva, which is transparent and therefore well suited for microscopy, the ETH researchers used Dendra 2 to colour neurons. They then focused the combined laser beam’s focal point on the cell body of a single neuron in a live, anesthetized zebrafish. The local Dendra 2 molecules became red, spread throughout the entire cell and dyed the cell extensions. All other cells, even in the immediate vicinity of the targeted cell, remained green.
The ability to make individual neurons visible could be of great importance, for example, in the precise mapping of the brain, according to Pantazis. Since the method is suitable for individual cell targeting in living organisms, it could also be used to examine dynamic processes; for example, what happens to individual cells or a group of molecules when researchers treat an organism with active pharmaceutical ingredients. Embryo development could also be examined in more detail. “Our method allows for a three-dimensional analysis in an elegant manner,” explains Pantazis. “This is a very nice example of how you can take a result from basic research and use it to provide a solution for a technically challenging issue.” Pantazis hopes the technique will be used more broadly in biomedical research in the future and is in talks with microscope manufacturers to implement this technology.
wavelength of light. ETH Zurich

Multiple sclerosis: cause of movement, balance problems

New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty “brake” within immune cells, a brake that should be controlling the inflammation. This points to a potential target for developing new therapies to treat multiple sclerosis and could have important implications for other autoimmune diseases, such as the colon disease colitis and the chronic skin condition atopic dermatitis.

Further, the work has produced new research models of multiple sclerosis symptoms such as movement disorders and balance control problems that have, until now, resisted efforts to mimic them effectively in the lab. These models represent important new tools in the efforts to better understand – and eventually cure – MS and other autoimmune conditions.

The researchers determined that a mutation in the gene Nlrp12 was causing immune cells known as T cells to go haywire. Normally, the researchers determined, the protein the gene produces acts as a brake within T cells to control the inflammatory response. But a mutation in that gene disrupts the natural process and provokes severe inflammation – with effects the researchers found most intriguing.

To the researchers’ surprise, the resulting inflammation did not produce the paralysis often associated with multiple sclerosis. It did, however, produce other MS symptoms — such as movement disorders and problems with balance control – which scientists have struggled to replicate in experimental lab settings.

“It’s important to note that MS is a spectrum disorder – some patients present with paralyzing conditions and some patients don’t,” said researcher John Lukens, PhD, of the University of Virginia School of Medicine Department of Neuroscience and its Center for Brain Immunology and Glia. “Not everybody’s symptoms are the same, so this might give us a glimpse into the etiology or pathogenesis of that family of MS.”

By blocking the inflammatory response, doctors may one day be able to control the symptoms it causes, both in MS and in other diseases driven by hyperinflammation. University of Virginia